Nurse Practitioner in Avenal, CA Accepting Medicare

7 Nurse Practitioner nurses found. Showing 1 - 7

Laramie Cosio Punzalan, Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 337 E Kings St, Avenal, CA 93204 Phone: 559-386-5200

Cony Rose Manalang Bencito, FNP-C Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 216 E Fresno St, Avenal, CA 93204 Phone: 559-386-5364

Ms. Petra G Baltierrez, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 1068 S 7th Ave, Apmt #33, Avenal, CA 93204 Phone: 559-386-9298

Mr. Jeffer Y Sabino, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 1000 Skyline Blvd, Avenal, CA 93204 Phone: 559-386-4500    Fax: 559-386-0550

Karen Marie Christensen, FNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 148 E Kings St, Avenal, CA 93204 Phone: 559-386-9000    Fax: 559-386-9090

Thanhan Mathews, NP Nurse Practitioner - Primary Care Medicare: Medicare Enrolled Practice Location: 148 E Kings St, Avenal, CA 93204 Phone: 559-386-9000

Melody Van Allen, NP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 1000 Skyline Blvd, Avenal, CA 93204 Phone: 559-386-4500

News Archive

Maintaining weight loss over long term can be a major challenge

A new report combining perspectives from a range of obesity experts identifies genetic, epigenetic and neuro-hormonal differences between individuals as one of the key challenges associated with weight loss and long-term weight control.

Sexual minority women more likely to smoke cigarettes when drinking alcohol, study finds

Sexual minority women are more likely to smoke cigarettes when drinking alcohol than heterosexual women, according to new University at Buffalo research.

Watson Pharmaceuticals receives FDA approval for generic Duragesic

Watson Pharmaceuticals, Inc. announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for fentanyl transdermal system in the 25, 50, 75 & 100 mcg/hour strengths.

AtriCure third quarter revenue increases $1.2 million to $14.5 million

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced revenue of $14.5 million for its seasonally impacted third quarter of 2010. Revenue from product sales in the United States was $11.6 million, reflecting growth of 8.1 percent and international revenue was $2.9 million, reflecting 19.2 percent growth on a constant currency basis or 12.7 percent on a GAAP basis.

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Onconova Therapeutics, Inc. today announced promising results from two clinical trials in patients with advanced Myelodysplastic Syndrome (MDS) treated with ON 01910.Na. These trials are being conducted at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, MD, and St. Vincent's Comprehensive Cancer Center in New York.

Read more Medical News

› Verified 6 days ago